Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Elan agrees to $8.3bn acquisition by Perrigo

Executive Summary

In its most expensive acquisition to date, OTC and generics firm Perrigo Co. is buying publicly traded Elan Corp. PLC for $8.3bn. For each Elan share (approximately 511.8mm), Perrigo will pay $6.25 in cash and issue 0.07636 in stock, equating to $16.17 per share, a 57% premium to Elan’s ten-day average prior to the February 2013 Royalty Pharma announcement.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash
    • Payment Includes Stock

Related Companies